1.Economic Burden of High-Responding Inhibitors in Patients with Hemophilia A in Taiwan.
Tsu Chiang TU ; Shin Nan CHENG ; Jye Daa CHEN ; Thau Ming CHAM ; Mei Ing CHUNG
Yonsei Medical Journal 2013;54(2):358-365
PURPOSE: Hemophilia A (HA) is the most common X-linked inherited bleeding disorder. In some patients with HA, particularly those with severe HA, replacement therapy results in the production of high-responding clotting factor VIII inhibitors. The economic burden of this complication is the highest reported for a chronic disease. Our aim was to investigate the direct medical expenditure burden of high-responding inhibitors in patients with HA. MATERIALS AND METHODS: A retrospective study was conducted using the National Health Insurance Research Database, utilizing data covering the period of 2004-2007. RESULTS: In total, 638 males with HA, including 37 patients with high-responding inhibitors were evaluated. Over 99% of the annual median medical expenditure was attributable to the cost of clotting factor concentrates (CFCs) in patients with high-responding inhibitors. The annual median expenditure related to CFCs of the total medical care and outpatient care were US$170611 and US$141982, respectively, and were 4.6- and 4.3-fold higher in these patients during the study period, respectively. In patients with high-responding inhibitors, the median hospitalization expenditure and daily hospitalization cost with or without surgical procedures were 3.0- and 2.4-fold higher, respectively, and 4.3 and 5.6-fold higher, respectively. CONCLUSION: Our data reveal higher medical expenditures burden for patients with HA and high-responding inhibitors in Taiwan. Future research is encouraged to evaluate the impact of this burden on patient quality of life.
*Cost of Illness
;
*Drug Resistance
;
Factor VIII/immunology/therapeutic use
;
Hemophilia A/*complications/drug therapy/economics
;
Hospitalization/economics
;
Humans
;
Male
;
*Quality of Life
;
Retrospective Studies
;
Taiwan
2.Prevalence, Incidence, and Factor Concentrate Usage Trends of Hemophiliacs in Taiwan.
Tsu Chiang TU ; Wen Shyong LIOU ; Tsui Yun CHOU ; Tsung Kun LIN ; Chuan Fang LEE ; Jye Daa CHEN ; Thau Ming CHAM ; Mei Ing CHUNG
Yonsei Medical Journal 2013;54(1):71-80
PURPOSE: Hemophilia A and B (HA, HB) are the most common X-linked inherited bleeding disorders. The introduction of factor concentrates has allowed for control of the lifelong chronic disease. However, no studies have been published regarding the epidemiology of hemophilia in Taiwan. Our aim was to determine the prevalence, incidence, and mortality rate, as well as trends in the use of factor concentrates, in individuals with hemophilia in Taiwan. MATERIALS AND METHODS: A retrospective study was conducted using the National Health Insurance Research Database between 1997 and 2007. RESULTS: We identified 988 males with hemophilia (HA : HB ratio=5.4 : 1). The mean prevalence per 100000 males was 6.7+/-0.1 for HA and 1.2+/-0.1 for HB. The estimated mean annual incidence per live male birth was 1 in 10752 for HA and 1 in 47619 for HB. Standardized mortality ratios for males with hemophilia (all severities) or severe hemophilia were 1.3- and 2.1-fold higher than that of the general male population, respectively. Mean factor VIII (FVIII) and factor IX (FIX) usage was 1.5003+/-0.4029 and 0.3126+/-0.0904 international units (IUs) per capita, respectively. Mean FVIII and FIX usage per patient with hemophilia (all severities) or severe hemophilia was 44027+/-11532 and 72341+/-17298, respectively, and 49407+/-13015 and 74369+/-18411 IUs per person with HA or HB, respectively. CONCLUSION: Our data revealed epidemiologic and factor concentrate usage trends in males with hemophilia in Taiwan, highlighting a need for improvements in the mandatory National Health Insurance registry. A better-designed, patient-centered registry system would enable more detailed patient information collection and analysis, improving subsequent care.
Adolescent
;
Adult
;
Aged
;
Child
;
Child, Preschool
;
Databases, Factual
;
Factor IX/therapeutic use
;
Factor VIII/therapeutic use
;
Hemophilia A/*drug therapy/*epidemiology/ethnology
;
Hemophilia B/*drug therapy/*epidemiology/ethnology
;
Humans
;
Incidence
;
Infant
;
Male
;
Middle Aged
;
Prevalence
;
Registries
;
Retrospective Studies
;
Taiwan/epidemiology
;
Young Adult